All News
EULAR 2025 - Day 1 Report
Wednesday was Day One at EULAR 2025 in Barcelona. Thousands from around the world gathered, eager to reunite at this international educational forum. Below are a few of my favorites from Day 1.
Read Article
Psoriatic Arthritis at Risk for Interstitial Lung Disease
A TriNetX EHR study shows that psoriatic arthritis, but not psoriasis, patients are at increased risk for interstitial lung disease (ILD).
Read Article
Nailfold Capillaroscopy correlated w/ cardiac ECHO in Systemic Sclerosis. NFC & ECHOs studied in 30 SSc pts. Systolic & diastolic dysfunction most common in late SSc NFC patterns. Cardiac dysfunction seen w/ low capillary density, avascular areas, cap neoangiogenesis https://t.co/pFBKjXqwfr
Dr. John Cush RheumNow ( View Tweet)
POCUS of the lung can detect subclinical ILD and can be a useful, inexpensive, easy to perform screening tool for CTD-ILD.
#EULAR2025 @RheumNow https://t.co/KpH05w1S9O
Adela Castro AdelaCastro222 ( View Tweet)
📊 In a 40-yr cohort (n=2818), RA pts had 2.3x ↑ risk of DVT (HR 2.26) & 1.6x ↑ risk of PE (HR 1.61) vs non-RA.
Risk ↑ with RF/CCP+, nodules (HR 2.9), BMI ≥30 (HR 1.9), & biologic use in year 1 (HR 2.4–2.9).
Remission = ↓ PE risk (HR 0.47)
đź“ŤOP0070
@RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
#EULAR2025 Abstr#OP0078 #Lupus nephritis is assoc with CVD. Propensity matched analysis comparing GLP-1 agonist vs SLGT2-i using TrinetX database in LN ->favourable risk reduction with GLP-1:
-CKD progression
-Mortality
-MI
Validation & mechanistic explanation needed @RheumNow https://t.co/xPDVDm1CHm
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
In propensity-matched RA cohort (n=2,449 each) on JAK inhibitors, adding a GLP-1 agonist reduced risk of: • Acute coronary syndromes (RR 0.65, p=0.0009) • DVT (RR 0.69, p=0.007) Overall CV events ↓ by 33% (RR 0.67, p=0.0007)
#EULAR2025 @RheumNow
Abstract#OP0069 https://t.co/jWI6tvri8O
Jiha Lee JihaRheum ( View Tweet)
RA pts have ↑ risk of DVT (HR 2.26) & PE (HR 1.61) vs controls in this 40-year, pop-based study. Nodules, obesity, high disease activity & early biologic use ↑ risk. Remission in year 1 halved PE risk. VTE risk persists despite therapeutic advances.
@RheumNow #EULAR2025 #OP0070 https://t.co/AaBi2o2cUw
Mrinalini Dey DrMiniDey ( View Tweet)
RA polygenic risk ≠MI risk. In >8,700 Swedes w/ or w/o RA, higher genetic risk for RA wasn’t linked to higher MI incidence. Familial clustering of RA & MI likely driven by non-genetic factors. Traditional CV risk still key in RA care.
@RheumNow #EULAR2025 #OP0072 https://t.co/KN6Dg0ekt2
Mrinalini Dey DrMiniDey ( View Tweet)
Clinical determinants of multiple drug failure in D2T RA
2000+ RA cohort 250+ refractory
-Low financial status
-Cancer Hx
-CV comorbidities
-Chronic use of NSAID or GCs
Protective: Regular participation in leisure activities
#POS0030 @RheumNow #EULAR2025 https://t.co/qNHQoHCb80
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
In >228k CTD patients across France, ILD increased mortality risk across all CTDs. Proportion of incident CTD with ILD highest in IIM (37%). Up to 34% of CTD-ILD pts had progressive pulm fibrosis. Supports earlier ILD screening & vigilance in CTDs.
@RheumNow #EULAR2025 #OP0033 https://t.co/KkF9xFY4Cn
Mrinalini Dey DrMiniDey ( View Tweet)
Ph 2 open label RCT TOFA in RA-ILD 52 wks
39pts 92% AE 8% 3 deaths FVC decline -69 ml
No diff between UIP, NSIP or antifibrotic
No control group
#POS0619 #EULAR2025 @RheumNow https://t.co/3lqEUfObG9
Aurelie Najm AurelieRheumo ( View Tweet)
Can lowering serum urate also lower CV risk? In >116k patients w/ #gout, achieving SU <360 µmol/L in 12m ↓ 5yr MACE risk (HR 0.89, pooled Δsurvival +1.4%). Greater effect in >65s. Gout management = CV prevention?
@RheumNow #EULAR2025 #OP0005 https://t.co/NRAerUBemN
Mrinalini Dey DrMiniDey ( View Tweet)
The American Heart Association just published their alcohol recommendations today which line up with the report by the National Academies. Moderate EtOH intake, up to 7 drinks per week (1/day), is without risk (and may be beneficial for cardiovascular outcomes)
@American_Heart https://t.co/7c0IlmgZiv
Eric Topol EricTopol ( View Tweet)
Psoriatic Arthritis at Risk for Interstitial Lung Disease
A TriNetX EHR study shows that psoriatic arthritis (PsA), but not Psoriasis (PsO), patients are at increased risk for interstitial lung disease (ILD).
https://t.co/2zuxF1PY3Q. https://t.co/r28dY3T8nO
Dr. John Cush RheumNow ( View Tweet)
Do SGLT2 and GLP-1 therapies have a role in Lupus?
Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-like peptide-1 receptor agonists (GLP1-RA), initially developed to lower glucose in Type 2 Diabetes, also provide cardiovascular and renal protection for patients https://t.co/JxnbgeqgOp
Dr. John Cush RheumNow ( View Tweet)
PPACMAN Consensus Recs. for CV risk in PSO/PSA published for Rheums/Derms/PCPs
- check BP, Wt, Lipids, Cr.
- Look for HTN, DM, smoking, obesity, metabolic synd.
- Risk stratify w/ hsCRP, Lipids
- Lifestyle management https://t.co/MkgYopTNAX https://t.co/fplKbua9Z2
Dr. John Cush RheumNow ( View Tweet)
PPACMAN Consensus Recs. for CV risk in PSO/PSA published for Rheums/Derms/PCPs
- check BP, Wt, Lipids, Cr.
- Look for HTN, DM, smoking, obesity, metabolic synd.
- Risk stratify w/ hsCRP, Lipids
- Lifestyle management https://t.co/MkgYopTNAX https://t.co/6yyxVIxpC0
Dr. John Cush RheumNow ( View Tweet)
Do SGLT2 and GLP-1 therapies have a role in Lupus?
Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-like peptide-1 receptor agonists (GLP1-RA), initially developed to lower glucose in Type 2 Diabetes, also provide cardiovascular and renal protection for patients https://t.co/8JEfcv2BUz
Dr. John Cush RheumNow ( View Tweet)
Valves Gone Wild in SLE
Lupus valvulitis is a rare cardiac manifestation of active systemic lupus erythematosus (SLE) and is defined by inflammation of one or more cardiac valves. It is often associated with Libman-Sacks endocarditis (LSE), which is characterized by the https://t.co/XcC2POFDRd
Dr. John Cush RheumNow ( View Tweet)
